Meta-analysis of GWAS data identifies genetic risk factors for inflammatory bowel disease in 125,992 individuals
Genetic map reveals new targets for inflammatory bowel disease
This meta-analysis review synthesizes genome-wide association study data from 125,992 individuals with IBD and more than 1.2 million control…
A massive genetic study found 619 new signals linked to Crohn's and ulcerative colitis, offering fresh clues for future treatments.
Meta-analysis associates childhood antibiotic use with increased inflammatory bowel disease risk
Early antibiotics may raise your risk of developing inflammatory bowel disease later in life
This meta-analysis of 8 studies involving 2783 cases examines the association between antibiotic use in children aged 1 to 17 years and the …
New research shows that taking antibiotics during childhood could increase the chance of developing inflammatory bowel disease later in life
Extended Risankizumab Benefits Initial Nonresponders in Ulcerative Colitis
Over half of ulcerative colitis patients found relief with longer treatment
Over 50% of patients with ulcerative colitis who did not respond to initial risankizumab achieved clinical response with 12 more weeks of ex…
More than half of patients with ulcerative colitis who did not respond to initial treatment found clinical response with extended risankizum…
Narrative review discusses NF-kB inhibition for inflammatory bowel diseases and related conditions
Blocking NF-κB May Ease Gut Inflammation in IBD
This narrative review explores the role of NF-kB pathway inhibition in treating inflammatory conditions.
A review finds that blocking a key inflammatory pathway could help treat Crohn's, colitis, and celiac disease.
Meta-analysis shows reduced oral microbial Shannon diversity in Crohn's disease versus controls
Oral bacteria shifts could reveal Crohn's disease risk
This meta-analysis reviews data from multiple cohorts involving 1,136 IBD patients and 759 controls.
A new study links distinct mouth bacteria changes to higher gut inflammation levels in Crohn's disease patients.
Enteral nutrition therapy associated with clinical remission in 60% of Chinese inflammatory bowel disease patients over 6 weeks
Enteral nutrition helps many IBD patients reach remission faster
This retrospective cohort study evaluated enteral nutrition therapy in 750 Chinese patients with Crohn's disease or ulcerative colitis.
Special liquid food formulas helped 60% of patients reach remission faster while improving nutrition and reducing inflammation in their bodi…
Three Biomarkers Show High Diagnostic Accuracy for Ulcerative Colitis in Cohort Study
Three biomarkers show promise for diagnosing ulcerative colitis
This cohort study evaluated ARHGEF3, S100A8, and RHOU as diagnostic biomarkers for ulcerative colitis.
A new study identifies three biomarkers that may help diagnose ulcerative colitis and distinguish it from Crohn's disease.
Network meta-analysis of dietary supplements for ulcerative colitis management
Some dietary supplements may help ulcerative colitis symptoms and quality of life
This network meta-analysis of 24 randomized controlled trials with 1,491 participants synthesized evidence on dietary supplements for ulcera…
A review of 24 trials found certain supplements like probiotics and flaxseed extract may ease ulcerative colitis symptoms and improve qualit…
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review
Why Hives Return to Old Injection Spots
This case report and literature review describes the first documented instance of vedolizumab-associated recall urticaria in a 25-year-old m…
A new case report reveals a rare skin reaction where hives return strictly to past injection sites.
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
The FDA has approved a new drug called Stelara for several inflammatory conditions
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
Narrative review discusses M cell manipulation limitations in inflammatory bowel disease models
Can we target gut cells without breaking the whole immune system?
This narrative review addresses challenges in selectively manipulating M cells within traditional animal models and two-dimensional culture …
Scientists are looking for ways to treat Crohn's disease and ulcerative colitis by focusing on specific cells in the gut lining.
All colitis Articles
- Meta-analysis of GWAS data identifies genetic risk factors for inflammatory bowel disease in 125,992 individuals
- Meta-analysis associates childhood antibiotic use with increased inflammatory bowel disease risk
- Extended Risankizumab Benefits Initial Nonresponders in Ulcerative Colitis
- Narrative review discusses NF-kB inhibition for inflammatory bowel diseases and related conditions
- Meta-analysis shows reduced oral microbial Shannon diversity in Crohn's disease versus controls
- Enteral nutrition therapy associated with clinical remission in 60% of Chinese inflammatory bowel disease patients over 6 weeks
- Three Biomarkers Show High Diagnostic Accuracy for Ulcerative Colitis in Cohort Study
- Network meta-analysis of dietary supplements for ulcerative colitis management
- First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review
- FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- Narrative review discusses M cell manipulation limitations in inflammatory bowel disease models
- Literature review synthesizes Schisandra chinensis effects on gut microbiota and metabolic pathways across multiple conditions
- Neutrophil SIRL-1/IL-8 Ratio as a Diagnostic Biomarker for Inflammatory Bowel Disease
- AI endoscopic score shows better agreement with ulcerative colitis remission than Mayo score in RCT
- Latent profiles of self-management behavior identified in Chinese ulcerative colitis patients
- Narrative review examines ulcerative colitis and colorectal cancer risk
- Cross-sectional data suggest IgG glycans discriminate inflammatory bowel disease from controls
- Guselkumab showed improved clinical remission in refractory ulcerative colitis versus placebo
- Meta-analysis finds increased VTE risk in pediatric IBD, especially ulcerative colitis
- Single-cell sequencing reveals T cell clonal patterns in healthy donors and ulcerative colitis patients
- PRO and Serum Biomarker Models Predict Endoscopic Activity in Ulcerative Colitis
- Meta-analysis of over 13 million births shows no association between Cesarean section and inflammatory bowel disease risk
- Vedolizumab plus curcumin improves remission in moderate-to-severe ulcerative colitis versus vedolizumab alone
- Single-cell and spatial technologies reveal UC pathogenesis insights but face sample size and phenotype heterogeneity limits
- Over 100 agents in development for moderate to severe ulcerative colitis, with early remission data for one class